证券代码：301257 证券简称：普蕊斯 公告编号：2025-069 一、股东减持计划实施情况 | 股东 名称 | 减持方式 | | | 减持期间 | | | 减持均价 （元/股） | 减持股数 （股） | 减持股数占总 股本比例（%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大宗交易 | 2025 | 年 10 | 月 | 14 | 日至 | 46.01 | 1,580,000 | 1.9999 | | 观由 | | 2025 | 年 | 11 | 月 6 | 日 | | | | | 昭泰 | 集中竞价 | 2025 | 年 11 | 月 | 10 | 日至 | 45.35 | 789,950 | 0.9999 | | | | 2025 | 年 | 12 | 月 5 | 日 | | | | | | | | 合计 | | | | | 2,369,950 | 2.9998 | 普蕊斯（上海）医药科技开发股份有限公司 关于公司股东减持计划实施完成的公告 公司股东上海观由投资发展有限公司－观由昭泰（嘉兴）创业投资合伙企业 ...

普蕊斯（上海）医药科技开发股份有限公司 简式权益变动报告书 上市公司名称：普蕊斯（上海）医药科技开发股份有限公司 股票上市地点：深圳证券交易所 股票简称：普蕊斯 股票代码：301257 信息披露义务人（一）：上海观由投资发展有限公司－观由昭泰（嘉 兴）创业投资合伙企业（有限合伙） 住所：浙江省嘉兴市南湖区南江路 1856 号基金小镇 1 号楼 104 室-17 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》及 《公开发行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》（以 下简称"《准则 15 号》"）及相关的法律、法规和规范性文件编写。 信息披露义务人（二）：新疆泰睿股权投资合伙企业（有限合伙） 住所：新疆石河子开发区北四东路 37 号 3-84 室 权益变动性质：股份减少、持股比例下降（大宗交易、集中竞价、因 公司实施 2022 年限制性股票激励计划被动稀释）、持股比例被动增 加（因公司回购注销限制性股票被动增加）。 签署日期：2025 年 11 月 24 日 1 信息披露义务人声明 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-068 普蕊斯（上海）医药科技开发股份有限公司 关于公司持股 5%以上股东及其一致行动人减持至 5% 暨权益变动的提示性公告 股东上海观由投资发展有限公司－观由昭泰（嘉兴）创业投资合伙企业（有 限合伙）及其一致行动人新疆泰睿股权投资合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动为股东减持，不触及要约收购； 2、本次权益变动后，股东上海观由投资发展有限公司－观由昭泰（嘉兴） 创业投资合伙企业（有限合伙）及其一致行动人新疆泰睿股权投资合伙企业（有 限合伙）合计持有公司股份 3,950,257 股，占公司总股本比例 5.0000%，不再是 公司持股 5%以上的股东； 3、本次权益变动不会导致公司控股股东、实际控制人发生变化。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于近日收到 公司合计持股 5%以上股东上海观由投资发展有限公司－观由昭泰（嘉兴）创业 投资合伙企业（有限合伙）（以下简称" ...

Group 1 - The company, Puris (SZ 301257), announced that it will conduct investor research from October 31, 2025, to November 21, 2025, with the participation of the board secretary, Lai Xiaolong [1] - As of the latest report, Puris has a market capitalization of 3.4 billion yuan [2] - For the first half of 2025, Puris reported that its revenue composition is entirely from the service industry, accounting for 100% [1]

Company Overview - Prasis is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [2] - As of Q3 2025, the company achieved revenue of CNY 219 million, a year-on-year increase of 9.84% [2] - The net profit for Q3 2025 was CNY 33.22 million, a significant increase of 3,322.54% year-on-year, with a non-GAAP net profit of CNY 31.13 million, up 120.72% [2] Operational Highlights - The company has undertaken over 4,200 SMO projects, with 2,538 currently in execution, and employs 4,271 staff [2] - The service network covers over 1,300 clinical trial institutions across multiple cities in China [2] - For the first three quarters of 2025, the profit distribution plan included cash dividends totaling CNY 5.37 million [2] Quality Management - The company has established over 280 standard operating procedures (SOPs) and 40 negative lists to ensure quality control [3] - Continuous training and assessment of employees, along with an internal quality control team, enhance project oversight [3] - No major findings were reported during inspections by national and international regulatory bodies [3] Digital Transformation - The company prioritizes the development and application of digital and intelligent technologies as a key growth strategy [3] - A collaborative clinical trial management platform is being developed, integrating AI and advanced quality management systems for improved efficiency [3] Client Structure and Revenue Recognition - The client base primarily consists of multinational pharmaceutical companies, domestic innovative drug companies, and CROs, with significant collaborations with the top 10 global pharmaceutical companies [3] - Clinical trial project cycles typically last 2-3 years, with revenue recognition influenced by various factors, leading to non-linear income distribution [3] Recruitment and Talent Development - As of September 2025, the company has a workforce of 4,271, with over 4,000 specialized personnel [3] - Recruitment plans are aligned with project needs and are supported by a robust training system to ensure quality [4]

Dividend Announcements - Jinlu Electronics announced a cash dividend of 0.1483572 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Deshi Co. declared a cash dividend of 1.40 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [1] - Shanghai Kaibao will distribute a cash dividend of 0.30 CNY for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [1] Additional Dividend Announcements - Shichang Co. announced a cash dividend of 5.80 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [2] - Mylande declared a cash dividend of 0.30 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] - Zhiyang Innovation announced a cash dividend of 0.10 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [2] Further Dividend Announcements - Shentong Technology declared a cash dividend of 0.027 CNY per share (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [3] - Jinshi Resources announced a cash dividend of 0.07 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] - Gibit declared a cash dividend of 6.00 CNY per share (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [3] Final Dividend Announcements - Puris announced a cash dividend of 0.68 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4] - Kaipu Testing declared a cash dividend of 2.00 CNY for every 10 shares (tax included), with the record date on November 27, 2025, and the ex-dividend date on November 28, 2025 [4]

Core Viewpoint - The company announced a profit distribution plan for the first three quarters of 2025, proposing a cash dividend of 0.68 RMB per 10 shares to all shareholders [1] Summary by Relevant Sections - **Profit Distribution Plan** - The company will distribute a cash dividend of 0.68 RMB for every 10 shares held by shareholders [1] - **Key Dates** - The record date for the dividend is set for November 27, 2025 - The ex-dividend date is scheduled for November 28, 2025 [1]

证券代码：301257 证券简称：普蕊斯 公告编号：2025-067 普蕊斯（上海）医药科技开发股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"、"本公司"） 于 2025 年 10 月 28 日召开了第三届董事会第十六次会议审议通过《关于 2025 年前三季度利润分配方案的议案》，此议案在 2025 年 5 月 20 日召开的 2024 年 年度股东大会授权范围内，无需再次提交公司股东会审议。现将权益分派事宜公 告如下： 一、股东会授权及董事会审议通过的利润分配方案情况 1、为践行常态化现金分红机制，提高投资者回报水平，简化现金分红决策 程序，公司于 2025 年 5 月 20 日召开 2024 年年度股东大会，审议通过了《关于 提请股东大会授权董事会进行中期分红方案的议案》，批准授权董事会在符合利 润分配的条件下制定具体的中期利润分配方案。 2、公司于 2025 年 10 月 28 日召开第三届董事会第十六次会议，在 2024 年 年度股东大会授权范 ...

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Group 1 - The shareholder Hongrun Yinke plans to reduce its holdings in the company by up to 6,500 shares, representing 0.0082% of the total share capital, within three months after the announcement [1] - The shareholder Shihezi Ruixin, an employee stock ownership platform, intends to reduce its holdings by up to 73,100 shares, which is 0.0925% of the total share capital, within three months after the announcement [2] - The company's financial director, Song Weihong, plans to reduce her indirect holdings by up to 73,100 shares and direct holdings by up to 800 shares, totaling a maximum reduction of 73,900 shares, which is 0.0935% of the total share capital [2] Group 2 - Hongrun Yinke has been established for over 10 years and is not controlled by the actual controller of the company [1] - Shihezi Ruixin holds 6,397,560 shares, accounting for 8.0977% of the total share capital [2] - Song Weihong's planned reduction does not exceed 25% of her total direct and indirect holdings [2]